Vivos Therapeutics amends 8-K to correct report date to Sept. 2, 2026
VVOS•8-K/A corrects report date and related transaction timing
Vivos Therapeutics filed an 8-K/A to correct the “Date of Report” in its Sept. 4 Form 8-K.
The filing changes the date to Sept. 2, 2026 from Aug. 31, 2026 for transactions under Items 1.01 and 3.02.
The corrected disclosure ties to exchanges with Streeterville Capital, converting $2.86 million of note principal into up to 11,445,080 shares.
These exchanges were consummated on Sept. 2, 2026; the remaining Streeterville Note principal balance was $3.7 million.
